ReviewFrontiers in oncology2019
Recent Advances in Understanding FOXN3 in Breast Cancer, and Other Malignancies.
Review in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Clinical significance of FOXN3 expression in Indian breast cancer patients.Scientific reports · 2025Article
- MiR-135b-5p promotes cetuximab resistance in colorectal cancer by regulating FOXN3.Cancer biology & therapy · 2024Article
- The nuclear GYF protein CD2BP2/U5-52K is required for T cell homeostasis.Frontiers in immunology · 2024Article
- FOXN3 Regulates Autophagic Activity to Suppress Drug Resistance in Melanoma Cells.Clinical, cosmetic and investigational dermatology · 2024Article
- FOXN3 inhibits the progression of ovarian cancer through negatively regulating the expression of RPS15A.Human cell · 2023Article
- Sex differences in the intergenerational link between maternal and neonatal whole blood DNA methylation: a genome-wide analysis in 2 birth cohorts.Clinical epigenetics · 2023Article
- Cytotoxicity of Isoxazole Curcumin Analogs on Chronic Myeloid Leukemia-Derived K562 Cell Lines Sensitive and Resistant to Imatinib.International journal of molecular sciences · 2023Article
- Acetylation of Checkpoint suppressor 1 enhances its stability and promotes the progression of triple-negative breast cancer.Cell death discovery · 2022Article
- Genome-wide decrease in DNA methylation in adults with epilepsy treated with modified ketogenic diet: A prospective study.Epilepsia · 2022Article
- Insights into the identification of a molecular signature for amyotrophic lateral sclerosis exploiting integrated microRNA profiling of iPSC-derived motor neurons and exosomes.Cellular and molecular life sciences : CMLS · 2022Article
- MAGI2-AS3 restrains proliferation, glycolysis, and triggers apoptosis in acute lymphoblastic leukemia via regulating miR-452-5p/FOXN3 pathway.Iranian journal of basic medical sciences · 2022Article
- Bioinformatic analysis of FOXN3 expression and prognostic value in pancreatic cancer.Frontiers in oncology · 2022Article
- FOXN3 inhibits cell proliferation and invasion via modulating the AKT/MDM2/p53 axis in human glioma.Aging · 2021Article
- Review
- MicroRNA-182 promotes epithelial-mesenchymal transition by targeting FOXN3 in gallbladder cancer.Oncology letters · 2021Article
- FOXF2 acts as a crucial molecule in tumours and embryonic development.Cell death & disease · 2020Review
- FOXA1 Suppresses the Growth, Migration, and Invasion of Nasopharyngeal Carcinoma Cells through Repressing miR-100-5p and miR-125b-5p.Journal of Cancer · 2020Article
- FOXN3 controls liver glucose metabolism by regulating gluconeogenic substrate selection.Physiological reports · 2019Article
- Micro RNAs Promoting Growth and Metastasis in PreclinicalCancer genomics & proteomicsReview
- miR-574-5p Targets FOXN3 to Regulate the Invasion of Nasopharyngeal Carcinoma Cells via Wnt/β-Catenin Pathway.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FOXN3 (forkhead box N3; CHES1: check point suppressor 1) belongs to the forkhead box (FOX) protein family. FOXN3 displays transcriptional inhibitory activity, and is involved in cell cycle regulation and tumorigenesis. FOXN3 is a tumor suppresser and alterations in FOXN3 are found in of a variety of cancers including melanoma, osteosarcoma, and hepatocellular carcinoma. While the roles of FOXN3 role in some cancers have been explored, its role in breast cancer remains unclear. Here we describe current state of knowledge of FOXN3 functions, and focus on its roles (known and potential) in breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.